AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT05714254
- Locations
- 🇩🇪
Research Site, Berlin, Germany
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4000
- Registration Number
- NCT05712096
- Locations
- 🇮🇱
Research Site, Ramat Gan, Israel
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT05702229
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
Completed
- Conditions
- COVID-19
- Interventions
- Other: ChAdOx1 nCOV-19 vaccine (Vaxzeria)Other: BNT162b2 (Pfizer)Other: Ad26.COV2.S (Janssen)Other: CoronaVac (Sinovac)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 188814085
- Registration Number
- NCT05697705
- Locations
- 🇧🇷
Techtrials Pesquisa e Tecnologia Ltda., São Paulo, Brazil
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05694741
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT05692180
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Phase 3
Active, not recruiting
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1350
- Registration Number
- NCT05687266
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
Completed
- Conditions
- SARS-CoV-2 Infection
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 366
- Registration Number
- NCT05687877
- Locations
- 🇯🇵
Research Site, Tottori, Japan
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05685472
- Locations
- 🇯🇵
Research Site, Kashiwa, Japan
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Active, not recruiting
- Conditions
- Small Cell Lung Carcinoma
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 254
- Registration Number
- NCT05683977
- Locations
- 🇫🇷
Research Site, Évreux, France
© Copyright 2025. All Rights Reserved by MedPath